Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CTSA | P10619 | 4/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4327338 | 0.88 | FFAR1 (0.48) | FFAR1CTSAFAAH | |
| SCHEMBL4322294 | 0.87 | FFAR2 (0.44) | CTSAHDAC8HDAC6KCNQ2 | |
| SCHEMBL4341821 | 0.87 | HDAC8 (0.40) | CTSAHDAC8HDAC6MMP9 | |
| SCHEMBL4329580 | 0.86 | FFAR1 (0.44) | FFAR1CTSAFAAH | |
| SCHEMBL4329478 | 0.84 | CTSA (0.39) | CTSAADAM17MMP13ANPEP | |
| SCHEMBL4328624 | 0.74 | HDAC3 (0.39) | CTSAHDAC8HDAC6 | |
| SCHEMBL4329821 | 0.74 | FFAR2 (0.41) | CTSA | |
| SCHEMBL4331353 | 0.74 | CTSA (0.41) | CTSA | |
| SCHEMBL4333159 | 0.73 | FFAR2 (0.39) | FFAR1CTSA | |
| SCHEMBL4343287 | 0.73 | CTSA (0.41) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | claimed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | claimed |
| US-7521563-B2 | Hydroxamic acid derivative and medicine containing the same as active ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | IL6, IL1A, TNF | FFAR1 1103/4885CTSA 1028/4885ADAM17 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.